SPRY PEER ANALYSIS

ARS Pharmaceuticals, Inc — metric-by-metric comparison with peers and the industry median

SPRYARS Pharmaceuticals, Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

SPRYIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	SPRY	MSB	TLX	RTALB	CSL	Ind. Median
P/E	—	—	—	4.89●	29.44	17.91
P/B	13.86	—	6.37	0.61●	2.20	3.51
EV/EBITDA	—	—	120.14	74.61	10.21●	14.82
P/S	8.59	31.61	3.24	6.67	2.62●	10.89

Financial Health
Metric	SPRY	MSB	TLX	RTALB	CSL	Ind. Median
Current Ratio	4.94●	—	1.43	1.21	2.57	5.90
Debt/Equity	157.4%	—	112.3%	1.2%●	67.4%	10.9%
NetDebt/EBITDA	0.54●	—	13.13	0.90	2.22	1.15

Profitability
Metric	SPRY	MSB	TLX	RTALB	CSL	Ind. Median
Net Margin	-200.0%	-115.3%	-0.9%	136.3%●	9.2%	-125.7%
ROE	-136.4%	-11.3%	-1.8%	15.1%●	7.7%	-47.5%
ROA	-64.4%	-8.6%	-0.7%	13.1%●	3.8%	-35.8%
EBITDA Margin	-194.1%	-76.6%	3.0%	9.0%	32.8%●	-105.8%

Growth + Dividend
Metric	SPRY	MSB	TLX	RTALB	CSL	Ind. Median
Rev. Growth	1.9%	410.4%●	56.3%	24.0%	4.8%	5.1%
NI Growth	—	—	—	134.0%●	-39.4%	12.1%
Div. Yield	—	0.0%	—	0.0%	2.5%●	0.2%
Payout	—	0.0%	—	0.0%	103.1%	0.0%

Valuation
Metric	SPRY	ZVRA	TBPH	MRVI	FDMT	CRMD	Ind. Median
P/E	—	—	7.58	—	—	4.49●	17.91
P/B	13.86	4.09	2.99	4.18	1.96	1.86●	3.51
EV/EBITDA	—	—	3.84	—	—	3.67●	14.82
P/S	8.59	—	7.91	4.32	10.03	2.03●	10.89

Financial Health
Metric	SPRY	ZVRA	TBPH	MRVI	FDMT	CRMD	Ind. Median
Current Ratio	4.94	4.89	13.14●	5.91	9.34	2.98	5.90
Debt/Equity	157.4%	0.6%●	25.2%	128.0%	4.5%	33.2%	10.9%
NetDebt/EBITDA	0.54	—	-2.26●	-1.01	2.27	-0.16	1.15

Profitability
Metric	SPRY	ZVRA	TBPH	MRVI	FDMT	CRMD	Ind. Median
Net Margin	-200.0%	—	104.3%●	-51.1%	-182.3%	45.2%	-125.7%
ROE	-136.4%	—	50.2%	-40.8%	-34.9%	65.6%●	-47.5%
ROA	-64.4%	—	28.1%	-12.5%	-31.3%	37.5%●	-35.8%
EBITDA Margin	-194.1%	—	129.8%●	-50.8%	-185.2%	53.2%	-105.8%

Growth + Dividend
Metric	SPRY	ZVRA	TBPH	MRVI	FDMT	CRMD	Ind. Median
Rev. Growth	1.9%	—	68.2%	-15.4%	383,560.9%●	384.6%	5.1%
NI Growth	—	—	—	—	—	953.6%	12.1%
Div. Yield	—	—	—	—	—	—	0.2%
Payout	—	—	—	—	—	—	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on SPRY

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.